Correlation of lipoprotein-associated phospholipase A2 and cerebral microbleeds in patients with acute ischaemic stroke

Zhang, Xiaojiu; Liu, Lu; Jiang, Nan; Liu, Yufeng; Wang, Qing; Tang, Xiaohong; Zhai, Qijin; Zhao, Liandong

doi:10.1186/s12883-022-03000-w

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, screening people with high risk of stroke recurrence is very important for the prevention and rescue of stroke. Because of its low invasiveness, low cost, and great conveniences, the development of blood biomarkers has been widely studied for stroke-onset prediction in recent years, and a series of biomarkers including alanine transaminase [ 13 ], phospholipase A2 [ 14 ], and neutrophil to lymphocyte ratio [ 15 ], etc. have been reported in succession.…”

Section: Discussionmentioning

confidence: 99%

Phenylacetyl glutamine: a novel biomarker for stroke recurrence warning

Liu

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

Background Stroke is the second leading cause of disease-related death and the third leading cause of disability worldwide. However, how to accurately warn of stroke onset remains extremely challenging. Recently, phenylacetyl glutamine (PAGln) has been implicated in the onset of stroke, but evidences from cohort studies of onset are lacking, especially in patients with first-onset or recurrent. It is necessary to deeply demonstrate the effectiveness of PAGln level on warning stroke onset. Methods One hundred fifteen first onset stroke patients, 33 recurrent stroke patients, and 135 non-stroke controls were included in the analysis. Risk factors associated with stroke attacking were evaluated, and plasma PAGln levels were detected via HPLC-MS based method. LASSO regression, Pearson correlation analysis, and univariate analysis were carried out to demonstrate the associations between PAGln levels and risk factors of stroke. Random forest machine learning algorithm was used to build classification models to achieve the distinction of first-onset stroke patients, recurrent stroke patients, and non-stroke controls, and further demonstrate the contribution of PAGln levels in the distinction of stroke onset. Results The median level of PAGln in the first-onset stroke group, recurrent stroke group, and non-stroke group was 933 ng/mL, 1014 ng/mL, and 556 ng/mL, respectively. No statistical correlation was found between PAGln level and subject’s living habits, eating preferences, and concomitant diseases (hypertension, hyperlipidemia, and diabetes). Stroke severity indicators, mainly age and NIHSS score, were found associate with the PAGln levels. Machine learning classification models confirmed that PAGln levels, as the main contributing variable, could be used to distinguish recurrent stroke patients (but not first-onset stroke patients) from non-stroke controls. Conclusion PAGln may be an effective indicator to monitor the recurrence in stroke patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Phenylacetyl glutamine: a novel biomarker for stroke recurrence warning

Liu

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…Our current research has found that Lp-PLA2 seems to be closely related to the occurrence and development of CMBs. 13 Other studies have already found that there is a relationship between the occurrence of inflammation and cognitive decline, 14,15 but whether Lp-PLA2, as an inflammatory factor, drives the occurrence and aggravation of CMBs and cognitive impairment is unclear.…”

Section: Introductionmentioning

confidence: 99%

Plasma Lipoprotein-Associated Phospholipase A2 Affects Cognitive Impairment in Patients with Cerebral Microbleeds

Liu¹,

Zhang²,

Jiang³

et al. 2023

NDT

Self Cite

View full text Add to dashboard Cite

Purpose The plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker of cerebral microbleeds (CMBs) and may be related to the occurrence, development, and prognosis of cognitive impairment. The present study aimed to investigate the impact of plasma Lp-PLA2 level on the cognitive impairment in patients with CMBs. Methods In this study, 213 patients with CMBs confirmed by 3.0 T brain magnetic resonance imaging (MRI) were analyzed. Lp-PLA2 levels were determined by magnetic particle chemiluminescence immunoassay technology, and cognitive function was assessed using the Montreal Cognitive Assessment Scale (MoCA). The cognitive functions of patients with CMBs were divided into three groups according to the MoCA scale, including normal cognition (NC), mild cognitive impairment (MCI), and moderate-severe cognitive impairment (MSCI). Clinical, laboratory and radiological data of the three groups were analysed. The relationship between plasma Lp-PLA2 and MoCA score in patients with CMBs was investigated through rank correlation analysis and multivariate regression analysis, and receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of Lp-PLA2. Results CMBs were detected in 213 (30.2%) of 705 patients who underwent 3.0 T MRI. Multiple comparisons showed that plasma Lp-PLA2 in patients with CMBs with normal cognitive scores was significantly lower than that in the other two groups with cognitive impairment ( p < 0.05). In the single factor correlation analysis, high level of plasma Lp-PLA2 was negatively correlated with the decrease of MoCA score in patients with CMBs ( r =−0.389, p < 0.01). Multivariate regression analysis showed that high plasma Lp-PLA2 was an independent risk factor for a low MoCA score in patients with CMBs (odds ratio [OR]=1.014; 95% confidence interval [CI], 1.002–1.026; p =0.025). Conclusion A high level of plasma Lp-PLA2 is positively correlated with the generation of cognitive impairment in patients with CMBs and negatively correlated with the degree of impairment. Plasma Lp-PLA2 is an important indicator of cognitive impairment in patients with CMBs and may provide a therapeutic target for preventing CMB-induced cognitive impairment.

show abstract